Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL; Spanish Group on IFN and CML. Peñarrubia MJ, et al. Ann Hematol. 2003 Dec;82(12):750-8. doi: 10.1007/s00277-003-0724-z. Epub 2003 Sep 27. Ann Hematol. 2003. PMID: 14517691 Clinical Trial.
Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
Steegmann JL, Requena MJ, Casado LF, Pico M, Peñarrubia MJ, Ferro MT, Resino M, Fernandez-Rañada JM. Steegmann JL, et al. Among authors: penarrubia mj. Am J Hematol. 1996 Nov;53(3):169-74. doi: 10.1002/(SICI)1096-8652(199611)53:3<169::AID-AJH4>3.0.CO;2-X. Am J Hematol. 1996. PMID: 8895687 Free article.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Sanz MA, et al. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14. Blood. 2010. PMID: 20393132 Free article. Clinical Trial.
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Montesinos P, et al. Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8. Blood. 2011. PMID: 21148082 Free article. Clinical Trial.
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Barragán E, et al. Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17. Haematologica. 2011. PMID: 21685470 Free PMC article.
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL. García-Gutiérrez V, et al. Among authors: penarrubia mj. Am J Hematol. 2014 Nov;89(11):E206-11. doi: 10.1002/ajh.23816. Epub 2014 Aug 27. Am J Hematol. 2014. PMID: 25059397 Free article.
58 results